London
24 °C
Manchester
18 °C
Glasgow
Dublin
Belfast
Washington
35 °C
Denver
25 °C
Atlanta
Dallas
Houston Texas
New Orleans
33 °C
El Paso
Phoenix
Los Angeles
25 °C
27 °C
3 °C
10 °C
26 °C
Zomedica's Fourth Friday at Four Webinar Returns: Spotlight on the Assisi(R) Line - Advancing Drug-Free Healing for Pets
NYSE - LSE
| CMSC | -0.28% | 22.547 | $ | |
| SCU | 0% | 12.72 | $ | |
| RYCEF | -1.36% | 13.2 | $ | |
| BCC | -1.74% | 84.67 | $ | |
| RBGPF | -4.75% | 74.03 | $ | |
| JRI | 0.68% | 13.15 | $ | |
| SCS | -1.45% | 10.36 | $ | |
| RIO | -4.96% | 59.325 | $ | |
| NGG | -0.35% | 70.275 | $ | |
| CMSD | -0.46% | 23.015 | $ | |
| BCE | -0.7% | 23.495 | $ | |
| VOD | -0.5% | 11.055 | $ | |
| GSK | 2.94% | 38.81 | $ | |
| RELX | -0.62% | 51.6 | $ | |
| BTI | 0.85% | 53.22 | $ | |
| AZN | 3.21% | 76.435 | $ | |
| BP | -2.92% | 32.025 | $ |
Zomedica's Fourth Friday at Four Webinar Returns: Spotlight on the Assisi(R) Line - Advancing Drug-Free Healing for Pets
Breakthrough tPEMF™ Technology Showcased in Monthly Series Exploring Innovation in Veterinary Care
ANN ARBOR, MI / ACCESS Newswire / July 16, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering advanced diagnostic and therapeutic solutions for companion and equine animals, is pleased to announce the next installment of its Fourth Friday at Four webinar series, scheduled for Friday, July 25, 2025 at 4:00 PM ET.
This month's session will highlight the Assisi line of products, Zomedica's suite of targeted Pulsed Electromagnetic Field (tPEMF) therapy devices that offer non-invasive, drug-free solutions for managing pain and inflammation in companion animals. Designed for both in-clinic and at-home use, the Assisi Loop®, Assisi Loop Lounge®, and Calmer Canine® products have become trusted tools for veterinarians and pet parents alike.
What to Expect:
A closer look at the science behind tPEMF therapy
Real-world success stories and clinical outcomes
How veterinarians are integrating Assisi products into daily care
Interactive Q&A with the Assisi and Zomedica teams
"Our Assisi Loop line of products represents the perfect blend of science, compassion, and innovation," said Nicole Westfall, Senior Vice President of Marketing at Zomedica. "We're excited to highlight how tPEMF therapy is helping animals heal faster, feel better, and live more comfortably-without relying on pharmaceuticals."
Mialisa Gluckert, Senior Director of Assisi Commercialization, added, "This month's webinar will offer an insider's perspective on how our customers are using Assisi products every day to support recovery, ease chronic conditions, and transform outcomes across veterinary practices. It's inspiring to see how far we've come-and where we're going next."
Whether you're a veterinary professional, industry partner, investor, or simply passionate about pet wellness, this webinar will provide valuable insights into the clinical, commercial, and compassionate impact of Assisi drug-free healing technology.
Webinar Registration & Details
Connect, Learn, and Discover What's Next in Veterinary Innovation
Don't miss your chance to connect with industry experts, get a firsthand look at groundbreaking veterinary technologies, and explore what's next in animal healthcare. Whether you're a veterinary professional, industry partner, investor, or simply passionate about helping our pets live healthier lives-this series is for you.
Reserve your spot for the next session by clicking the link below:
Zomedica 4th Friday at Four Registration
Or head to: www.investors.zomedica.com
About Zomedica
Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW® digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. Zomedica grew revenue 8% in 2024 to $27 million and maintains a strong balance sheet with approximately $65 million in liquidity as of March 31, 2025. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as we work to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information visit www.zomedica.com.
Follow Zomedica
Cautionary Note Regarding Forward-Looking Statements
Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements and our ability to realize upon our business plans and cost control efforts.
Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, including international efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to realize the anticipated growth opportunities from our acquisitions; uncertainty as to our ability to supply products in response to customer demand; supply chain risks associated with tariff changes; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products and purchase of consumables following adoption of our capital equipment; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contact:
Zomedica Investor Relations
[email protected]
1-734-369-2555
SOURCE: Zomedica Corp.
View the original press release on ACCESS Newswire
W.Fortin--SMC
